| |
original article |
Date |
Title |
Authors All Authors |
| 1 |
[GO] |
2025―Nov―11 |
In Silico Evaluation of Structural Consequences in the Human CYP3A4 Caused by Molnupiravir-Induced Mutations During COVID-19 Treatment |
Madhumita Aggunna, Chiranjeevi V. M. Ganteti, Keerthi R. Bhukya, Meghana Mathangi, Joyjethin Neelam, Aswitha Gurrala, et al. (+5) Bavana Grandhi, Noahjeevan Vejendla, Sriharshini Mathangi, Swarnalatha Gudapati, Ravikiran S. Yedidi |
| 2 |
[GO] |
2025―Oct―30 |
Discovery and Characterization of 7,8-Dihydropyrido[4,3-d]pyrimidines as SARS-CoV-2 Entry Inhibitors |
Sean P. Bradley, Jazmin M. Galván Achi, Laura Cooper, Malaika D. Argade, Han Cheng, Ryan Bott, et al. (+9) Christian A. Zielinski, Arsen M. Gaisin, Luke T. Jesikiewicz, José A. Villegas, Hyun Lee, Kiira Ratia, Norton P. Peet, Lijun Rong, Irina N. Gaisina |
| 3 |
[GO] |
2025―Oct―23 |
Correction: Tabatabaei et al. SARS-CoV-2 and Coronaviruses: Understanding Transmission, Impact, and Strategies for Prevention and Treatment. Drugs Drug Candidates 2025, 4, 5 |
Seyede Nafise Tabatabaei, Zahra Keykhaee, Saghi Nooraei, Mohammad Amin Ayati, Mohammad Behzadmand, Saba Azimi, et al. (+2) Fatemeh Eskati, Gholamreza Ahmadian |
| 4 |
[GO] |
2025―Jun―16 |
Plants Metabolites as In Vitro Inhibitors of SARS-CoV-2 Targets: A Systematic Review and Computational Analysis |
Brendo Araujo Gomes, Diégina Araújo Fernandes, Thamirys Silva da Fonseca, Mariana Freire Campos, Patrícia Alves Jural, Marcos Vinicius Toledo e Silva, et al. (+17) Larissa Esteves Carvalho Constant, Andrex Augusto Silva da Veiga, Beatriz Ribeiro Ferreira, Ellen Santos Magalhães, Hagatha Bento Mendonça Pereira, Beatriz Graziela Martins de Mattos, Beatriz Albuquerque Custódio de Oliveira, Stephany da Silva Costa, Flavia Maria Mendonça do Amaral, Danilo Ribeiro de Oliveira, Ivana Correa Ramos Leal, Gabriel Rocha Martins, Gilda Guimarães Leitão, Diego Allonso, Simony Carvalho Mendonça, Marcus Tullius Scotti, Suzana Guimarães Leitão |
| 5 |
[GO] |
2025―Mar―28 |
Advancing Viral Defense: Unravelling the Potential of Host-Directed Antivirals Against SARS-CoV-2 |
Zheng Yao Low, Siau Wui Chin, Sharifah Syed Hassan, Wee Sim Choo |
| 6 |
[GO] |
2025―Feb―11 |
SARS-CoV-2 and Coronaviruses: Understanding Transmission, Impact, and Strategies for Prevention and Treatment |
Seyede Nafise Tabatabaei, Zahra Keykhaee, Saghi Nooraei, Mohammad Amin Ayati, Mohammad Behzadmand, Saba Azimi, et al. (+2) Fatemeh Eskati, Gholamreza Ahmadian |
| 7 |
[GO] |
2024―Jan―05 |
In Silico Therapeutic Study: The Next Frontier in the Fight against SARS-CoV-2 and Its Variants |
Calvin R. Wei, Zarrin Basharat, Godwin C. Lang’at |
| 8 |
[GO] |
2023―Sep―28 |
Bioactive Components of Myracrodruon urundeuva against SARS-CoV-2: A Computational Study |
Sabrina Kelly Silva Alves, Cássio Silva Sousa, Edilanne Katrine Amparo Viana, Hellen Cris Araújo Souza, Maycon Douglas Araújo Souza, Arthur Serejo Neves Ribeiro, et al. (+4) Vanessa de Sousa do Vale, Muhammad Torequl Islam, Joabe Lima Araújo, Jefferson Almeida Rocha |
| 9 |
[GO] |
2023―May―31 |
Effect of the N501Y Mutation on Ligands Complexed with SARS-CoV-2 RBD: Insights on Potential Drug Candidates for COVID-19 |
Camila Fonseca Amorim da Silva, Samanta Omae Camalhonte, Michell de Oliveira Almeida, Sheila Cruz Araujo, Miriam Sannomiya, João Henrique Ghilardi Lago, Kathia Maria Honorio |
| 10 |
[GO] |
2022―Dec―02 |
Failed Repurposing of Lysosomotropic Drugs for COVID-19 Treatment or Prevention |
François Marceau |
|
